Circulating Tumor Cell Composition in Renal Cell Carcinoma

• Ivonne Nel ,

  Contributed equally to this work with: Ivonne Nel, Thomas C. Gauler

  ¶‡ These authors are co-first authors on this work.

  Affiliations Molecular Oncology Risk-Profile Evaluation, Department of Medical Oncology, West German Cancer Center, University Duisburg-Essen, Essen, Germany, ABA GmbH & Co. KG, BMZ2, Dortmund, Germany

  ⨯
• Thomas C. Gauler ,

  Contributed equally to this work with: Ivonne Nel, Thomas C. Gauler

  ¶‡ These authors are co-first authors on this work.

  Affiliations Molecular Oncology Risk-Profile Evaluation, Department of Medical Oncology, West German Cancer Center, University Duisburg-Essen, Essen, Germany, Department of Radiotherapy, University of Duisburg-Essen, Essen, Germany

  ⨯
• Kira Bublitz,

  Affiliation Molecular Oncology Risk-Profile Evaluation, Department of Medical Oncology, West German Cancer Center, University Duisburg-Essen, Essen, Germany

  ⨯
• Lazaros Lazaridis,

  Affiliation Molecular Oncology Risk-Profile Evaluation, Department of Medical Oncology, West German Cancer Center, University Duisburg-Essen, Essen, Germany

  ⨯
• André Goergens,

  Affiliation Institute for Transfusion Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany

  ⨯
• Bernd Giebel,

  Affiliation Institute for Transfusion Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany

  ⨯
• Martin Schuler,

  Affiliations Department of Radiotherapy, University of Duisburg-Essen, Essen, Germany, Department of Medical Oncology, West German Cancer Center, University Duisburg-Essen, Essen, Germany

  ⨯
• Andreas-Claudius Hoffmann

  * E-mail: hoffmann@more-oncology.com

  Affiliations Molecular Oncology Risk-Profile Evaluation, Department of Medical Oncology, West German Cancer Center, University Duisburg-Essen, Essen, Germany, Department of Medical Oncology, West German Cancer Center, University Duisburg-Essen, Essen, Germany

  ⨯